Application Form - European Medicines Agency by lonyoo

VIEWS: 109 PAGES: 19

									                                European Medicines Agency
                                Evaluation of Medicines for Human Use




                                                                                         London, 1 April 2009
                                                                                          EMEA/210134/2008




                  Medicinal Products for Human Use

            Administrative information
Application form for a Scientific Opinion according
    to Article 58 of Regulation (EC) 726/2004

                                          April 2009




                       7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
                          Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 51
                     E-mail: mail@emea.europa.eu http://www.emea.europa.eu
   European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged.
                                          APPLICATION FORM

                                    SUMMARY OF THE DOSSIER
                                                    
                 APPLICATION FORM : ADMINISTRATIVE DATA

This application form is to be used for an application for a CHMP Scientific Opinion in the context of
co-operation with the World Health Organization (WHO) for the evaluation of medicinal products intended
exclusively for markets outside the Community for human use submitted to the European Medicines
Agency.

A combined application form is acceptable (information on each pharmaceutical form and strength should
be provided successively, where appropriate).

DECLARATION and SIGNATURE

       Product (invented) name:


       Strength(s):


       Pharmaceutical form:


       Active substance(s):


       Applicant:

       Person authorised for
       communication*, on behalf
       of the applicant :

It is hereby confirmed that all existing data which are relevant to the quality, safety and efficacy of
the medicinal product have been supplied in the dossier, as appropriate.
It is hereby confirmed that fees will be paid.
On behalf of the applicant: ___________________________________________
                             Signature(s)
                             ___________________________________________
                             NAME*
                             ___________________________________________
                             Function
                             ___________________________________________
                             Place                 date (yyyy-mm-dd)

*      Note: please attach letter of authorisation for communication/signing on behalf of the applicant in annex 5.4




                                                                                                                  2/19
Table of contents

Declaration and signature

1.    TYPE OF APPLICATION
1.1   This application concerns
1.2   Application for a fundamental change to a existing CHMP Scientific Opinion
1.3   Description of the type of application
1.4   Consideration of this application is also requested under certain situations
1.5   Paediatric studies


2.    CHMP SCIENTIFIC OPINION APPLICATION PARTICULARS
2.1   Name(s) and ATC code
2.2   Strength, pharmaceutical form, route of administration, container and pack sizes
2.3   Legal status
2.4   CHMP scientific opinion holder / contact
2.5   Manufacturers
2.6   Qualitative and quantitative composition


3.    SCIENTIFIC ADVICE

4.    INFORMATION ABOUT THE MEDICINAL PRODUCT

5.    ANNEXED DOCUMENTS




                                                                                         3/19
1.       TYPE OF APPLICATION

Note:    The following sections should be completed where appropriate.

1.1.     THIS APPLICATION CONCERNS:

        A CHMP SCIENTIFIC OPINION (according to Article 58 Regulation (EC) No 726/2004)



Date of WHO letter:                        Date of CHMP elibibility:   
(See Annexes 5.19)                  (dd-mm-yyyy)                                         (dd-mm-yyyy)


 Rapporteur: _________________                     Co-rapporteur: _________________
(Name of CHMP member)                              (Name of CHMP member)


1.2.     IS THIS AN APPLICATION FOR A CHANGE TO YOUR EXISTING CHMP SCIENTIFIC OPINION

                Yes     (complete sections below and also complete section 1.3)

                No      (complete section 1.3. only)


                  Is the present application a line extension

                  Yes (complete section 1.2.1)

                 No (complete section 1.2.2)
1.2.1.
             Is the change to your existing CHMP scientific opinion considered to be a “line extension”?
             Please specify:

              change or addition of a new pharmaceutical form
              change or addition of a new strength/potency
              change or addition of a new route of administration
              change of pharmacokinetics
              change of bioavailability
              addition/change of indication in a different therapeutic area (therapeutic area is defined as the
             third level of the ATC code)
              qualitative change in declared active substance not defined as a new active substance:

             replacement by a different salt/ester, complex/derivative (same therapeutic moiety)
             replacement by a different isomer, mixture of isomers, of a mixture by an isolated isomer
              replacement of a biological substance or product of biotechnology
              other change(s), please specify:




 Note: The changes proposed in Annex II of Regulation (EC) No. 1085/2003, as amended are applied
by analogy.

  Note: If clarification needed, please refer to the definition in the Notice to Applicants, vol. 2A, chapter 1.
                                                                                                              4/19
1.2.2.         Is the change to your existing CHMP scientific opinion not considered to be a “line
               extension”? Please specify:

               addition of one or more active substance(s) including antigenic components for vaccines
               deletion of one or more active substance(s) including antigenic components for vaccines
                qualitative change in declared active substance defined as a new active substance:

               replacement by a different salt/ester, complex/derivative (same therapeutic moiety)
                replacement by a different isomer, mixture of isomers, of a mixture by an isolated isomer
               replacement of a biological substance or product of biotechnology
               other change(s), please specify:





    Note: If clarification needed, please refer to the definition in the Notice to Applicants, vol. 2A, chapter 1.
                                                                                                                5/19
1. 3.      DESCRIPTION OF THE TYPE OF APPLICATION


- The application submitted is a complete dossier composed of administrative information, complete
quality data, non-clinical and clinical data based on the applicants‟ own tests and studies and/or
bibliographic literature substituting for/supporting certain tests or studies1.

            New active substance.

            Known active substance.

 The application submitted is a „well established use‟ application composed of administrative
information, complete quality data, non-clinical and clinical data based on bibliographic literature
substituting all non-clinical tests and clinical studies2.
 The application submitted is a „new fixed combination‟ application composed of administrative
information, complete quality data, non-clinical and clinical data based on the applicants‟ own tests and
studies and/or bibliographic literature substituting for/supporting certain tests or studies relating to a
combination of active substances3.

 The application submitted is an „informed consent‟ application composed of administrative
information, quality, non-clinical and clinical data with a letter from <name of the MAH> allowing the
cross-reference to relevant quality, non-clinical and/or clinical data4.

           Attach letter from MAH (Annex 5.2).

- The application submitted is a „generic‟ application composed of administrative information, complete
quality data and at least a bioequivalence study with the reference medicinal product <name of reference
medicinal product> instead of non-clinical and clinical unless justified otherwise5.

           Reference medicinal product:

                      ■Medicinal product which is or has been authorised:
                       Product name, strength(s), pharmaceutical form(s):
                       Marketing authorisation holder:
                       Date of authorisation (yyyy-mm-dd):
                       Marketing authorisation number(s) if applicable:
                       Marketing authorisation granted by:
                                  o Community
                                  o EU/EEA Member State:
                                  o Non-EU/EEA Member State:

                      ■ Medicinal product which is or has been authorised to which bioequivalence has been
                      demonstrated by appropriate bioavailability studies:

                       Product name, strength(s), pharmaceutical form(s):
                       Marketing authorisation holder:
                       Date of authorisation (dd-mm-yyyy):
                       Marketing authorisation(s) granted by:
                                  o Community
                                  o EU/EEA Member State:
                                  o Non-EU/EEA Member State:

1
  As described in Article 8(3) of Directive 2001/83/EC (so-called full complete and full/mixed application).
2
  As described in Article 10(a) of Directive 2001/83/EC.
3
  As described in Article 10(b) of Directive 2001/83/EC.
4
  As described in Article 10(c) of Directive 2001/83/EC.
5
  As described in Article 10(1) of Directive 2001/83/EC.

                                                                                                               6/19
                          Marketing authorisation number(s) if applicable:
                          Member State of source:
                          Bioavailability study reference numbers/EudraCT numbers if applicable:

 The application submitted is a „hybrid‟ application composed of administrative information, complete
quality data, a clinical bioequivalence study with the reference medicinal product <name of reference
medicinal product> and with the appropriate applicant‟s non-clinical and clinical data6.

              Reference medicinal product:
                     ■Medicinal product which is or has been authorised:
                      Product name, strength(s), pharmaceutical form(s):
                      Marketing authorisation holder:
                      Date of authorisation (yyyy-mm-dd):
                      Marketing authorisation number(s) if applicable:
                      Marketing authorisation granted by:
                                 o Community
                                 o EU/EEA Member State:
                                 o Non-EU/EEA Member State:

               Difference(s) compared to this reference medicinal product:
                     change in the active substance(s)
                     change in therapeutic indication(s)
                     change in pharmaceutical form(s)
                     change in strength (quantitative change to the active substance(s))
                     change in route of administration
                     bioequivalence cannot be demonstrated through bioavailability studies

                        ■ Medicinal product which is or has been authorised used for the demonstration of
                        bioequivalence (if applicable) and/or in other studies.

                         Study reference number/EudraCT number:
                         Product name, strength(s), pharmaceutical form(s):
                         Marketing authorisation holder*:
                         Marketing authorisation(s) granted by:
                                   o Community
                                   o EU/EEA Member State:
                                   o Non-EU/EEA Member State:

                          Marketing authorisation number(s) if applicable:
                          Member State of source:

- The application submitted is a „similar biological‟ application composed of administrative information,
complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product 7.

              Reference medicinal product:

                        ■Medicinal product which is or has been authorised:
                         Product name, strength(s), pharmaceutical form(s):
                         Marketing authorisation holder:
                         Date of authorisation (yyyy-mm-dd):
                         Marketing authorisation number(s) if applicable:
                         Marketing authorisation(s) granted by:

6
    As described in Article 10(3) of Directive 2001/83/EC.
7
    As described in Article 10(4) of Directive 2001/83/EC.

                                                                                                            7/19
                             o   Community
                             o   EU/EEA Member State:
                             o   Non-EU/EEA Member State:

         ■ Difference(s) compared to this reference medicinal product:
                 change(s) in the raw material(s)
                 change(s) in the manufacturing process(es)
                 change in therapeutic indication(s)
                 change in pharmaceutical form(s)
                 change in strength (quantitative change to the active substance(s))
                 change in route of administration(s)
                 other

                ■ Medicinal product which is or has been authorised and to which comparability tests
                and studies have been conducted:
                 Product name, strength(s), pharmaceutical form(s):
                 Marketing authorisation holder:
                 Date of authorisation (yyyy-mm-dd):
                 Marketing authorisation number(s) if applicable:
                 Marketing authorisation(s) granted by:
                            o Community
                            o EU/EEA Member State:
                            o Non-EU/EEA Member State:

1.4.     CONSIDERATION OF THIS APPLICATION IS ALSO REQUESTED UNDER THE FOLLOWING SITUATIONS



1.4.1.         Conditional Opinion
                Note: As described in Article 14(7) of Regulation (EC) No 726/2004 for centralised
                procedure, by analogy.

1.4.2.         Opinion under exceptional circumstances
                Note: As described in Article 22 of Directive 2001/83/EC and Article 14(8) of Regulation
                (EC) No 726/2004, by analogy.

1.4.3.         Shortened evaluation
                Note: As described in Article 14(9) of Regulation (EC) No 726/2004 for centralised
                procedure, by analogy.

                 Date of acceptance by CHMP:
                 (yyyy-mm-dd)


1.5.     PAEDIATRIC STUDIES:
         (note: The pediatric requirements do not apply to Art 58 applications since these requirements
         apply to medicinal products authorised in the Community or intended to be authorised in the
         Community. Most medicinal products falling under the framework of Article 58 would have a
         potential use in the paediatric population. Applicants are therefore encouraged to discuss the
         development of such products for the paediatric population in an EMEA/CHMP scientific advice
         procedure. Scientific advice for paediatric questions are free of charge).


          This application does not include any paediatric studies.
          This application does include paediatric studies.



                                                                                                          8/19
2. CHMP SCIENTIFIC OPINION APPLICATION PARTICULARS

2.1. Name(s) and ATC code

2.1.1   Proposed (invented) name of the medicinal product:


If different (invented) names in different countries are proposed, these should be listed in Annex 5.1

2.1.2 Name of the active substance(s):


Note:    Normally only one name should be given in the following order of priority: INN*, Ph.Eur., National
        Pharmacopoeia, common name, scientific name. If other references are used please specify and
        justify:


        * the active substance should be declared by its recommended INN, accompanied by its salt or
        hydrate form if relevant (for further details, consult the EU Guideline on the SPC).


2.1.3   Pharmacotherapeutic group (please use current ATC code):


   ATC Code:                                     Group:


   If no ATC code has been assigned, please indicate if an application for ATC code has been made:

2.2. Strength, pharmaceutical form, route of administration, container and pack sizes

2.2.1   Strength and pharmaceutical form (use in principal the current list of standard terms -
        European Pharmacopoeia)

Pharmaceutical form:

Active substance(s)                                       Strength(s)




                                                                                                         9/19
2.2.2 Route(s) of administration (use in principal the current list of standard terms - European
Pharmacopoeia):




2.2.3 Container, closure and administration device(s), including description of material from which it is
        constructed. (use in principal the current list of standard terms - European Pharmacopoeia)


For each type of pack give:

2.2.3.1    Package size(s):

2.2.3.2    Proposed shelf life:

2.2.3.3    Proposed shelf life (after first opening container):

2.2.3.4    Proposed shelf life (after reconstitution or dilution):

2.2.3.5    Proposed storage conditions:

2.2.3.6    Proposed storage conditions after first opening:


2.3       Legal status

2.3.1     Proposed dispensing/classification
                subject to medical prescription

                 not subject to medical prescription

2.3.2     For products subject to medical prescription:

                  product on prescription which may be renewed (if applicable)
                  product on prescription which may not be renewed (if applicable)
                  product on special prescription
                  product on restricted prescription

Not all options listed are applicable outside the Community. Applicants are invited to indicate which
categories they are requesting, but countries outside the Community reserve the right to apply only those
categories provided for in their national legislation.


2.4.      CHMP scientific opinion holder/contact

2.4.1 Proposed CHMP scientific opinion holder/contact point responsible for placing the
product on the market outside the Community:

          (Company) Name:
          Address:
          Country:
          Telephone:
          Telefax:
          E-mail:

                                                                                                        10/19
        Contact person at this address:
          Attach proof of establishment of the applicant/contact point in the EEA (Annex 5.3)

Has SME status been assigned by the EMEA?

               No
               Yes
                EMEA SME number:
        Date of expiry:       (yyyy-mm-dd)
          Attach copy of the „Qualification of SME status‟ (Annex 5.8)


2.4.2   Person/company authorised for communication on behalf of the applicant during the
        procedure:

        Name:                                        If different to 2.4.1 above,
        Company name:                               Attach letter of authorisation (Annex 5.4)
        Address:
        Country:
        Telephone:
        Telefax:
        E-mail:


2.4.3 Person authorised for communication between the scientific opinion holder and the competent
authorities after adoption of the opinion by CHMP:

        Name:                                        If different to 2.4.1 above,
        Company name:                               Attach letter of authorisation (Annex 5.4)
        Address:
        Country:
        Telephone:
        Telefax:
        E-mail:


2.4.4 Responsible person for Pharmacovigilance

        Name:
        Company name:
        Address:
        Country:
        24 H Telephone:
        Telefax:
        E-mail:

            Attach C.V. of responsible person for pharmacovigilance (Annex 5.5)




                                                                                                 11/19
2.5     Manufacturers
Note: ALL manufacturing and control sites mentioned throughout the whole dossier MUST be consistent
regarding their names, detailed addresses and activities.
2.5.1. Contact person responsible for any quality issues:

       Name:
       Address:
       Country:
       24h contact telephone number:
       Telefax:
       E-mail:
  Attach C.V. of responsible person for any quality issues (Annex 5.6)


2.5.2. Batch control/Testing arrangements
Site(s) where batch control/testing takes place

        Company name:
        Address:
        Country:
        Telephone:
        Telefax:
        E-mail:

Brief description of control test carried out by the laboratory(ies) concerned:

   Attach copy of manufacturing authorisation(s) or other proof of GMP compliance (Annex 5.7)
       or
   Enter EudraGMP manufacturing authorisation reference:


2.5.3 Manufacturer(s) of the medicinal product and site(s) of manufacture:
(Note: include manufacturing sites of any diluents or solvents presented in a separate container but forming
part of the medicinal product, quality control or in-process testing sites, and importers)

        Company name:
        Address:
        Country:
        Telephone:
        Telefax:
        E-mail:

        Brief description of functions performed:

          Attach flowchart indicating the sequence and activities of the different sites involved in the
manufacturing process, including testing sites (Annex 5.9)

         Site is in the EEA:
           - Manufacturing authorisation number:

                 Attach manufacturing authorisation(s) (Annex 5.7)
            or
                 Enter EudraGMP manufacturing authorisation reference:

            If available:

                                                                                                           12/19
         Attach latest GMP certificate (Annex 5.10)
    or
         Enter EudraGMP certificate reference number:



 Site is outside the EEA:
        Attach document equivalent of manufacturing authorisation (Annex 5.7)

   - Has the site been inspected for GMP compliance by an EEA authority or by an
   authority of countries where MRA or other Community arrangements apply within the
     terms of the agreement?

     no                  yes

    If yes, please provide in Annex 5.10:
        a statement less than three years old from the competent authority which carried out the
    inspection,
    or,
    If available:
        Attach latest GMP certificate
    or
        Enter EudraGMP certificate reference number:

   - Has the site been inspected for GMP Compliance by any other authority (including those
   of countries where MRA or other Community arrangements apply but not within their
   respective territory)?

     no                  yes

        If yes, please provide summary information in Annex 5.10 (and, if available a GMP
    certificate or a statement from the competent authority which carried out the
    inspection)


2.5.4 Manufacturer(s) of the active substance(s) and site(s) of manufacture
Note: All manufacturing sites involved in the manufacturing process of each source of active
substance, including quality control / in-process testing sites, should be listed. Brokers or
 supplier details alone are not acceptable. For biotechnology products include all sites of storage
of master and working cell bank and preparation of working cell banks.
or Note: only the final manufacturer(s) to be mentioned

Active substance:
Company name:
Address:
Country:
Telephone:
Telefax:
E-mail:

Brief description of manufacturing steps performed by manufacturing site:
   Attach flowchart indicating the sequence and activities of the different sites involved in the
manufacturing process, including batch control sites (Annex 5.9)



                                                                                                    13/19
For each active substance, attach information on the contact person responsible for any
    quality issues (Annex 5.6)

    - Has the site been inspected for GMP compliance by an EEA authority or by an authority of
    countries where MRA or other Community arrangements apply within the
    terms of the agreement?
       no            yes

      If yes, please provide in Annex 5.10:
           a statement from the competent authority that carried out the inspection,
      or,
      If available:
          Attach latest GMP certificate
      or
          Enter EudraGMP certificate reference number:

    - Has the site been inspected for GMP compliance by any other authority (including those of
      countries where MRA or other Community arrangements apply but not within their
    respective territory)?
        no           yes

          If yes, please provide summary information in Annex 5.10 (and, if available a GMP
           certificate or a statement from the competent authority which carried out the inspection)

     Has a Ph.Eur. Certificate of suitability been issued for the active substance(s):
      no              yes              Provide copy in Annex 5.11
    If yes,
    - substance:
    - name of the manufacturer:
    - reference number:
    - date of last update (yyyy-mm-dd):

     Is a Active Substance Master File (European Drug Master File) to be used for the active
    substance reference/original?
     no               yes
    If yes,
    - substance:
    - name of the manufacturer:
            - reference number for EMEA / competent authority:
            - date of submission (yyyy-mm-dd):
            - date of last update (yyyy-mm-dd):
            -     attach letter of access for Community/Member State authorities where the application
            is made (see “European ASMF procedure for active ingredients”) (Annex 5.11)
            -     attach copy of written confirmation from the manufacturer of the active substance to
            inform the applicant in case of modification of the manufacturing process or specifications
            according to Annex I of Directive 2001/83/EC, by analogy (Annex 5.12)

     Is an EMEA certificate for a Vaccine Antigen Master File (VAMF) being used for this Scientific
    Opinion?
      no          yes                Provide copy in Annex 5.17




                                                                                                       14/19
If yes,
             - substance name:
             - name of the VAMF certificate holder or applicant:
             - reference number of application or certificate:
             - date of submission (if pending) (yyyy-mm-dd):
             - date of approval or last update (if approved) (yyyy-mm-dd):

(Section to be copied as necessary for all VAMFs cross-referenced)



2.5.5 Contract companies used for clinical trial(s) on bioavailability or bioequivalence or used
       for the validation of blood product manufacturing processes.
      For each contract company, state where analytical tests are performed and where clinical data
       are collected and give:

             Title of the study:
             Protocol code:
             EudraCT number (if applicable):
             Name of the company:
             Address:
             Country:
             Telephone:
             Telefax:
             Email:
             Duty performed according to contract:


2.6          Qualitative and quantitative composition

2.6.1        Qualitative and Quantitative composition in terms of the active substance(s) and the
             excipient(s):

      A note should be given as to which quantity the composition refers (e.g. 1 capsule)

      List the active substance(s) separately from the excipient(s):

      Name of active substance(s)*           Quantity         Unit           Reference/Monograph standard




      etc.
      Name of excipient(s)*                  Quantity         Unit           Reference/Monograph standard




      etc.



                                                                                                        15/19
Note: * Normally only one name should be given in the following order of priority: INN**, Ph.Eur.,
  National Pharmacopoeia, common name, scientific name; if other references are used please specify and
  justify:
        ** the active substance should be declared by its recommended INN, accompanied by its salt or
        hydrate form if relevant (for further details, consult the Guideline on the SPC)

   Details of any overages should not be included in the formulation columns but stated below:

   - active substance(s):
   - excipient(s):




                                                                                                   16/19
2.6.2   List of materials of animal and/or human origin contained or used in the manufacturing
        process of the medicinal product?
                             NONE
          Name Function*               Animal origin      Other Human          Certificate of origin
                                       susceptible to     animal origin        suitability for TSE
          AS        EX           R     TSE**                                   (state number)

  1.                                                                                      
  2.                                                                                      
  3.                                                                                      
  4.                                                                                      

etc.

* AS: active substance; EX: excipient (including starting materials used in the manufacture of the active
substance/exipient), R: reagent/culture medium (including those used in the preparation of master and
working cell banks).
** as defined in section 2 (scope) of the CHMP note for guidance.
   If a Ph. Eur. Certificate of Suitability for TSE is available according to Resolution AP/CSP (99)4 of the
Council of Europe attach it in Annex 5.13

2.6.3   Is an EMEA certificate for a Plasma Master File (PMF) being used for this Scientific
        Opinion?

         no              yes              Provide copy in Annex 5.18

        If yes,
        - Substance referring to PMF:
                  function*
                 AS EX R
                          
        - name of the PMF certificate holder/PMF applicant:
        - reference number of application/certificate:
        - date of submission (if pending) (yyyy-mm-dd):
        - date of approval or last update (if approved) (yyyy-mm-dd):

* AS: active substance; EX: excipient (including starting materials used in the manufacture of the active
substance/excipient); R: reagent/culture medium (including those used in the preparation of master and
working cell banks)
        (Section to be copied as necessary for all PMFs cross-referenced)

2.6.4   Does the medicinal product contain or consist of Genetically Modified Organisms (GMOs)?

         No              Yes

        If yes, does the product comply with Council Directive 90/220/EEC, by analogy?

         No              Yes

            Attach a copy of any written consent of the competent authorities to the deliberate release into
        the environment of the GMOs for research and development purposes where provided for by Part B
        of the above-mentioned Directive, by analogy (Annex 5.14)

                                                                                                            17/19
3.       SCIENTIFIC ADVICE

3.1.   Was there formal scientific advice given by the CHMP for this medicinal product?

          No             Yes

         If yes,

         Date (yyyy-mm-dd):
         Reference(s) of the scientific advice:
            Attach copy of the scientific advice (Annex 5.15)



4. INFORMATION ABOUT THE MEDICINAL PRODUCT

4.1. Marketing authorisation applications for the same product outside the EEA
(i.e. from applicants belonging to the same mother company or group of companies OR which are
“licensees” for products with the same qualitative and quantitative composition of active substance(s) and
the same pharmaceutical form)

     Authorised
         country:
         date of authorisation (yyyy-mm-dd):
         invented name:

             Attach marketing authorisation (Annex 5.16)

     Pending
         country:
         date of submission (yyyy-mm-dd):

     Refused
         country:
         date of refusal (yyyy-mm-dd):

     Withdrawn (by applicant before authorisation)
         country:
         date of withdrawal:
         invented name:
         reason for withdrawal (yyyy-mm-dd):

     Withdrawn (by applicant after authorisation)
         country:
         date of withdrawal (yyyy-mm-dd):
         authorisation number:
         reason for withdrawal:
         invented name:

     Suspended/revoked (by competent authority)
         country:
         date of suspension/revocation (yyyy-mm-dd):
         reason for suspension/revocation:
         trade name:


                                                                                                        18/19
5.         ANNEXED DOCUMENTS (WHERE APPROPRIATE)

     5.1   List of proposed different (invented) names in different countries.

     5.2   Letter from MAH allowing cross reference to relevant quality, non-clinical and/or clinical data.

     5.3   Proof of establishment of the applicant/contact point in the EEA.

     5.4   Letter of authorisation for communication on behalf of the applicant/contact point.

     5.5   Curriculum vitae of the responsible person for pharmacovigilance.

     5.6   Curriculum vitae of the responsible person for any quality issues.

     5.7   Manufacturing authorisation required under Article 40 of Directive 2001/83/EC (or
           equivalent, outside of the EEA where MRA/PECA is in operation.

     5.8   Copy of the „Qualification of SME Status‟.

     5.9 Flowchart indicating all manufacturing and control sites involved in the manufacturing process of
     the medicinal product and the active substance (including sites involved in sampling and testing for batch
     release of products manufactured in third countries)

     5.10 GMP certificate(s) or other GMP statement(s). Where applicable, a summary of other GMP
     inspections performed.

     5.11 Letter(s) of access to Active Substance Master File(s) or copy of Ph. Eur. Certificate(s) of
          Suitability.

     5.12 Copy of written confirmation from the manufacturer of the active substance to inform the applicant
     in case of modification of the manufacturing process or specifications.

     5.13 Ph. Eur. Certificate(s) of suitability for TSE.

     5.14 Written consent(s) of the competent authorities regarding GMO release in the environment.

     5.15 Scientific Advice given by CHMP.

     5.16 Copy of marketing authorisation(s) or equivalent in third countries (a photocopy of the pages
     which give the marketing authorisation number, the date of authorisation and the page which has been
     signed by the authorising competent authority will suffice).

     5.17 Copy of EMEA certificate for a Vaccine Antigen Master File (VAMF).

     5.18 Copy of EMEA certificate for a Plasma Master File (PMF).

     5.19 Copy of letters from WHO and EMEA/CHMP regargding eligibilty under Article 58 of Regulation
     (EC) No 726/2004.




                                                                                                          19/19

								
To top